Oncternal Therapeutics Insiders
ONCTDelisted Stock | USD 0.53 0.00 0.00% |
Oncternal Therapeutics employs about 27 people. The company is managed by 9 executives with a total tenure of roughly 63 years, averaging almost 7.0 years of service per executive, having 3.0 employees per reported executive. Breaking down Oncternal Therapeutics' management performance can provide insight into the firm performance.
Oncternal |
Oncternal Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.7645) % which means that it has lost $0.7645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4986) %, meaning that it created substantial loss on money invested by shareholders. Oncternal Therapeutics' management efficiency ratios could be used to measure how well Oncternal Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Oncternal Therapeutics Workforce Comparison
Oncternal Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,174. Oncternal Therapeutics holds roughly 27.0 in number of employees claiming about 2.3% of equities under Health Care industry.
Oncternal Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Oncternal Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Oncternal Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Oncternal Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Oncternal Therapeutics Notable Stakeholders
An Oncternal Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Oncternal Therapeutics often face trade-offs trying to please all of them. Oncternal Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Oncternal Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Pablo Urbaneja | Senior Development | Profile | |
Anita Wiseth | Senior Resources | Profile | |
Gunnar Kaufmann | Chief Officer | Profile | |
Chase JD | General Secretary | Profile | |
Salim MD | Chief Officer | Profile | |
Chase Leavitt | General Secretary | Profile | |
Steven Hamburger | VP Assurance | Profile | |
Richard CPA | Treasurer CFO | Profile | |
Rajesh Krishnan | Chief Officer | Profile |
About Oncternal Therapeutics Management Performance
The success or failure of an entity such as Oncternal Therapeutics often depends on how effective the management is. Oncternal Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Oncternal management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Oncternal management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. Oncternal Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.
Please note, the imprecision that can be found in Oncternal Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Oncternal Therapeutics. Check Oncternal Therapeutics' Beneish M Score to see the likelihood of Oncternal Therapeutics' management manipulating its earnings.
Oncternal Therapeutics Workforce Analysis
Traditionally, organizations such as Oncternal Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Oncternal Therapeutics within its industry.Oncternal Therapeutics Manpower Efficiency
Return on Oncternal Therapeutics Manpower
Revenue Per Employee | 29.1K | |
Revenue Per Executive | 87.2K | |
Net Loss Per Employee | 1.5M | |
Net Loss Per Executive | 4.4M | |
Working Capital Per Employee | 1.1M | |
Working Capital Per Executive | 3.4M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Oncternal Stock
If you are still planning to invest in Oncternal Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncternal Therapeutics' history and understand the potential risks before investing.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Stocks Directory Find actively traded stocks across global markets | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |